FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and is intended for treating inflammatory gastrointestinal diseases, including ulcerative colitis and Crohn's disease. Invention also relates to methods of introducing integrin beta7 antagonists, such as anti-beta7 antibodies. Invention also relates to specific dosing regimens, including dosing regimens, including subcutaneous administration.
EFFECT: group of inventions provides higher clinical effectiveness and reduces degree of severity of disease.
71 cl, 8 dwg, 6 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTI-BETA 7 ANTAGONISTIC ANTIBODIES AND USE THEREOF | 2005 |
|
RU2453558C2 |
| USE OF IL-13 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DERMATITIS | 2017 |
|
RU2752785C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING AND VEGF ANTAGONISTS | 2013 |
|
RU2689760C2 |
| ANTIBODIES TO FGFR2 IN COMBINATION WITH CHEMOTHERAPY IN CANCER TREATMENT | 2018 |
|
RU2797560C2 |
| FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
| METHOD OF TREATING VASCULITIS | 2005 |
|
RU2411956C2 |
| ANTIBODY-DRUG CONJUGATES AND METHODS OF USING SAID CONJUGATES OF PYRROLOBENZODIAZEPINE | 2016 |
|
RU2736725C1 |
| METHODS FOR DIAGNOSING AND TREATING RELATED TO TH2 INHIBITION | 2011 |
|
RU2578468C2 |
| METHODS OF TREATING CHRONIC POUCH ILEITIS | 2018 |
|
RU2822135C2 |
| DIAGNOSTICS AND TREATMENT METHODS ASSOCIATED WITH TH2 INHIBITION | 2011 |
|
RU2737245C2 |
